Readouts, trials and R&D strategy.
The US company reported a $0.7 million third-quarter net loss, alongside Canadian clearance for its oral testosterone and the start of the BLOOM study of LPCN 1154.
The US biotech reported Q3 2026 results, with Novartis milestones of $87.5 million and cash of $582.6 million expected to fund operations into 2029.
The CAR-T developer says Descartes-08 data in AChR antibody-positive myasthenia gravis are due in the first quarter of 2027, ahead of a planned FDA filing, as it reports Q3 2026 results.
The US cell therapy developer expects registrational myositis data in the second half of 2027 and has opened a systemic sclerosis cohort, with cash of $299.4 million.
Climb Bio's Q3 2026 update reports sustained APRIL suppression at 12 weeks for CLYM116, a Phase 2 IgA nephropathy start, and cash expected to last into H2 2028.
An independent safety board found no serious adverse events in the first PBGENE-DMD patient through week eight and endorsed treating more patients in Part 1 of FUNCTION-DMD.
Amylyx reported positive Phase 3 LUCIDITY results alongside Q3 figures, saying it will file with the FDA by the end of 2026 for avexitide, which has Breakthrough Therapy Designation.
UCB will use Cradle's AI-driven protein engineering platform in selected discovery projects, from hit generation to preclinical readiness, with no financial terms disclosed.
The US obesity drug developer reported Q3 results, saying it has $1.04bn in cash expected to fund operations into mid-2028.